vphm, it's got a lot more room to run. >> all aboard! >> the new viropharma doesn't care about boring antibiotics. it's got a whole slate of sexy orphan drugs, the kind that wall street gets so excited about it. we have all these companies on air. they've got even more coming down the pipeline. first there's simrise for a disorder that can cause swelling in the face and the extremities. can send a person to the hospital. if the swelling happens in the upper airways, it can be life threatening. they have the only therapy on the market that is designed to prevent these attacks from happening, which is why they can charge something like $350,000 a year for the treatment. which is viropharma's new drug. the company bought it from a place called lev pharmaceutical. they paid $500 million. five months later, they got fda approval. and last august, they finally got industrial scale approval. which means the company can manufacture as much of the drug that it wants. when viropharma purchased them in 2008, they initially forecasted the drug could